Ski Acts as Therapeutic Target of Qingyihuaji Formula in the Treatment of SW1990 Pancreatic Cancer

Abstract

Background. Qingyihuaji formula (QYHJ) is a widely used herbal formula that has shown promising antitumor effect in the treatment of pancreatic cancer in the Cancer Hospital, Fudan University, Shanghai, China. Objective. This research was conducted to study whether Ski acts as a therapeutic target of QYHJ formula in the treatment of SW1990 pancreatic cancer. Methods. The expression changes of Ski mRNA and protein in SW1990 pancreatic cancer subcutaneously transplanted tumor treated with QYHJ were detected by real-time polymerase chain reaction and Western blot. Then, we established a stable transfection SW1990 cell with low expression of Ski through lentivirus-mediated RNA interference (RNAi) technique. The responses to QYHJ treatment on a subcutaneously transplanted tumor with different Ski expression statuses were evaluated. Finally, the effect of Ski downregulation on SW1990 cell biological behavior was also evaluated. Results. Expression of Ski mRNA and protein in SW1990 subcutaneously transplanted tumor decreased dramatically after the treatment with QYHJ. Stable transfection cells with low expression of Ski (SW1990/Ski RNAi) were created, and negative vector-transfected cells (SW1990/con RNAi) were used as controls. The tumor weight inhibitory rates of QYHJ on subcutaneously transplanted tumors formed by SW1990 or SW1990/con RNAi were 29.6% and 32.2%, respectively, whereas they were 16.0% to 17.8% when the tumors were formed by SW1990/Ski RNAi. Ski downregulation sensitized the response of SW1990 cells to TGF-β1-induced growth inhibition in vitro. Flow cytometric analyses revealed that the percentage of cells in the G1 phase increased from 40.4% to 62.9% when Ski was downregulated. The subcutaneously transplanted tumors formed by SW1990/Ski RNAi grew much more slowly than those formed by parental and control vector—transfected cells. Conclusion. Ski acts as therapeutic target of QYHJ in the treatment of SW1990 pancreatic cancer cells, and its expression status mediates different responses to QYHJ treatment.

Keywords

Qingyihuaji formula (QYHJ)pancreatic cancer Ski RNA interference

References

Liu L. , Wu L. , Lin S. , et al. Therapeutic evaluation on advanced pancreatic cancer treated by integrative Chinese and western medicine: clinical analysis of 56 cases . Chin J Integr Med. 2004;10:236-237.

Shen Y. , Liu L. , Chen Z. , et al. Study on Chinese medicine combined with chemotherapy for treatment of 32 cases of advanced pancreatic cancer. Tradit Chin Med . 2006;47:115-117.

Shen Y. , Liu L. , Shen J. , et al. Impact of Qingyihuaji formula on proliferation and cell cycle of experimental pancreatic cancer in vivo. Chin J Basic Med Tradit Chin Med. 2006;12:97-99.

Shen Y. , Liu L. , Lu Y. , et al. Impact of Qingyixiaoji decoction on gene expression of experimental pancreatic cancer in vivo. Zhonghua Zhong Liu Za Zhi. 2005;15:454-457, 461.

Akiyoshi S. , Inoue H. , Hanai J. , et al. c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. J Biol Chem. 1999;274: 35269-35277.

Luo K. , Stroschein SL , Wang W. , et al. The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev. 1999;13:2196-2206.

Sun Y. , Liu X. , Eaton EN , et al. Interaction of the Ski oncoprotein with Smad3 regulates TGF-beta signaling. Mol Cell. 1999;4:499-509.

Xu W. , Angelis K. , Danielpour D. , et al. Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. Proc Natl Acad Sci U S A. 2000; 97:5924-5929.

Reed JA , Bales E. , Xu W. , et al. Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling. Cancer Res. 2001;61:8074-8078.

10.

Fukuchi M. , Nakajima M. , Fukai Y. , et al. Increased expression of c-Ski as a co-repressor in transforming growth factor-beta signaling correlates with progression of esophageal squamous cell carcinoma. Int J Cancer. 2004;108:818-824.

11.

Buess M. , Terracciano L. , Reuter J. , et al. Amplification of Ski is a prognostic marker in early colorectal cancer. Neoplasia. 2004;6:207-212.

12.

Heider TR , Lyman S. , Schoonhoven R. , et al. Ski promotes tumor growth through abrogation of transforming growth factor-beta signaling in pancreatic cancer. Ann Surg . 2007;246:61-68.

13.

Ritter M. , Kattmann D. , Teichler S. , et al. Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia. Leukemia. 2006;20:437-443.

14.

Mamidipudi V. , Zhang J. , Lee KC , et al. RACK1 regulates G1/S progression by suppressing Src kinase activity. Mol Cell Biol. 2004;24:6788-6798.

15.

Lu XG , Zhan LB , Feng BA , et al. Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by d-limonene. World J Gastroenterol . 2004;10:2140-2144.

16.

Shao ZM , Nguyen M. , Alpaugh ML , et al. The human myoepithelial cell exerts antiproliferative effects on breast carcinoma cells characterized by p21WAF1/CIP1 induction, G2/M arrest, and apoptosis. Exp Cell Res. 1998;241: 394-403.

17.

Jemal A. , Siegel R. , Ward E. , et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.

18.

Liu E. , Xiang Y. , Jin F. , et al. Cancer incidence trends in urban Shanghai,1972-1999. Tumor. 2004;24:11-15.